



## CONFERENCE AGENDA 2024

[Last updated: November 1, 2024]

### Friday, November 1

12:00-12:30pm

#### Welcome and Keynote Address

##### Welcome

- **Laura Esserman**

**Keynote:** The Launch of the Birth Control Pill and How it Should Inform Decisions Today

- **Elizabeth (Liz) Watkins**, University of California, Riverside

12:30-2:00pm

#### Session 1: Tumor Classification in Optimizing Therapy and Outcomes

**Co-Chairs:** **Laura van 't Veer**, University of California, San Francisco

**Lajos Pusztai**, Yale University

**Advocate:** **Amy Delson**, UCSF Breast Science Advocacy Core

##### Invited Speaker

- Response Predictive Subtypes (RPS): origins, evolution, and future directions  
**Denise Wolf**, University of California, San Francisco

##### Selected Abstract Presentations

- Analysis of I-SPY2-990 Data to Reveal New Pathways of Resistance in Response Predictive Subtype-Negative and Response Predictive Subtype-Discordant Breast Cancers  
**Tam Binh V. Bui**, University of California, San Francisco
- Improving risk stratification and prediction of response to neoadjuvant therapy (NAT) by serial monitoring of circulating tumor DNA (ctDNA) in high-risk early-stage breast cancer  
**Mark Magbanua**, University of California, San Francisco
- The steroid hormone receptor signature (SRS) in stage II/III triple negative breast cancer correlates with highly actionable functional protein drug target activation and is associated with early recurrence  
**Julie Wulfschlegel**, George Mason University
- Examining APOBEC3B in TCGA and ICGC Breast Cancer Datasets Reveals Altered Drug Metabolism Pathways  
**Joel Pardo**, University of Minnesota

##### Invited Speaker

- Diagnosis 2030: What AI Can (and Can't) do for you  
**Alexander (Sandy) Borowsky**, University of California, Davis

##### Advocate Perspective

- **Amy Delson**

##### Summary Panel

2:15-3:45pm

#### Session 2: Imaging as a Predictive Marker and Early Endpoint in Clinical Trials

**Co-Chairs:** **Nola Hylton**, University of California, San Francisco



## RISE UP for Breast Cancer

**Advocates:** *Elissa Price*, University of California, San Francisco  
*Diane Heditsian*, UCSF Breast Science Advocacy Core  
*Jan Tomlinson*, UCSF Breast Science Advocacy Core

### Invited Speaker

- Ultrafast MRI in Post Treatment Assessment  
*Yiming Gao*, New York University

### Patient Perspectives

*Diane Heditsian and Jan Tomlinson*

### Selected Abstract Presentations

- Temporal Changes in Mammographic Breast Density as a Predictive Biomarker Across the Breast Cancer Continuum  
*Gretchen Gierach*, National Cancer Institute
- Real World Study of the Effect of T+Ai on Background Parenchymal Enhancement (BPE)  
*Wayne Tilley*, University of Adelaide
- Interim Results from a Multimodality Screening Program Reveal Low Recall Rates and Breast Cancer Detection in BRCA Mutation Carriers Undergoing Biannual DCE-MRI  
*Hatice Basdag*, University of Chicago
- Short-term Declines in Breast Density by Treatment-Associated Endocrine Symptoms After Tamoxifen Therapy: Examining the Role of CYP2D6 phenotype and Tamoxifen Metabolites  
*Cody Ramin*, Cedars Sinai Medical Center
- Validation of an MRI-Based Predictive Model for Treatment Tailoring in the I-SPY 2 Trial  
*Wen Li*, University of California, San Francisco

### Panel Discussion

3:45-4:15pm

**Break and Exhibitors**  
**Light Refreshments**

4:15-6:30pm

### Session 3: Increasing Efficacy While Decreasing Toxicity of Local and Systemic Therapy

**Co-Chairs:** *Hope Rugo*, University of California, San Francisco  
*Silvia Formenti*, Weill Cornell Medicine  
**Advocate:** *Jane Mortimer*, UCSF Breast Science Advocacy Core

### Introduction

**Debate:** Radiation Therapy Can Be Safely Avoided in Patients with Women Age 50 or Older With Stage I non TNBC

- **YES:** *Bruce Mann*, Royal Women's Hospital, Melbourne, Australia
- **NO:** *Nicolas Prionas*, University of California, San Francisco
- **Rebuttal**
- **Summary**  
*Silvia Formenti*, Co-Chair and *Jane Mortimer*, Advocate

### Selected Abstract Presentations



## RISE UP for Breast Cancer

- Heart and Left Anterior Descending Coronary Artery (LAD) exposure from hypofractionated whole breast radiotherapy with a prone set up  
**Fabiana Gregucci**, Weill Cornell Medicine
  - Vaginal/Sexual Health (VSH) in Patients with ER+/HER2-Metastatic Breast Cancer (mBC)  
**David Portman**, Sermonix Pharmaceuticals
  - No Longer a “Necessary Evil” – Managing Genitourinary Syndrome of Menopause in Cancer Survivors  
**Catherine Lu Dugan**, University of Southern California
  - **Panel Q&A** (Co-Chair Moderators)
- Debate:** Is pCR enough to limit systemic therapy?
- **YES:** **Rita Nanda**, University of Chicago
  - **NO:** **Cesar Santa-Maria**, Johns Hopkins University
  - **Rebuttal**
  - **Summary**  
**Hope Rugo**, Co-Chair and **Jane Mortimer**, Advocate

6:30-7:30pm

**Poster Session 1: Tumor Classifier, Imaging Endpoints, Toxicity Reduction**  
**Appetizers**

7:30-8:30pm

**Evening Reception**  
**Buffet Dinner**

## Saturday, November 2

7:00-8:00am

**Breakfast**

8:00-9:30am

**Session 4: Risk Prediction and Biomarkers for Prevention Trials**

**Co-Chairs:** **Laura Fejerman**, University of California, Davis  
**Adetunji Toriola**, Washington University St. Louis

**Advocate:** **Ricki Fairley**, Touch, The Black Breast Cancer Alliance

**Introduction**

**Adetunji Toriola**, Co-Chair

**Selected Abstract Presentations**

- Senescence-Based Deep Learning Predicts Breast Cancer Risk Using H&E Core Biopsy Images from Healthy Women  
**Mark Powell**, Buck Institute for Research on Aging
- Predicting Risk of Future Breast Cancer Based on Screening MRI Features  
**Suleeporn Sujichantararat**, University of Washington
- Stromal Inflammation as a Driver of Parity-related Breast Cancer Etiologic Heterogeneity: Implications for Precision Prevention in a Sub-Saharan African Population  
**Mustapha Abubakar**, National Cancer Institute



## RISE UP for Breast Cancer

- Characterizing the Immune and Non-Immune Landscape of Premalignant and Preinvasive Breast Lesions  
**Vagmi Luhar**, National Cancer Institute
- An AI Risk Model for Digital Breast Tomosynthesis to Predict Breast Cancer and Guide Clinical Care  
**Mikael Eriksson**, Karolinska Institutet

### Advocate Presentation

**Ricki Fairley**

### Session Summary

**Laura Fejerman**, Co-Chair

9:35-11:30am

## Session 5: Applying the Lessons of Breast Cancer Biology to Early Phase Prevention Trials

**Co-Chairs:** **Carol Fabian**, University of Kansas

**Andrea De Censi**, University of Genoa

**Advocate:** **Valerie Fraser**, SWOG Cancer Research Network-PAC

### Introduction

**Carol Fabian**, Co-Chair

### Invited Speaker

- Preventing Breast Cancer with Molecules Targeting the Estrogen Receptor: An Excursion into Translational Drug Development  
**Barry Komm**, Consultant

### Selected Abstract Presentations

- DCIS: RECAST – An Adaptive Platform Trial to Identify Women with Hormone Receptor Positive DCIS who are Candidates for Active Surveillance  
**Kelly Hewitt**, University of Utah
- Refining tamoxifen dose for premenopausal breast cancer risk reduction (RENAISSANCE). A Phase II Single-Arm Trial  
**Seema Khan**, Northwestern University
- Beneficial Effects of Bazedoxifene Plus Conjugated Estrogens (Duavee) on Breast Cancer Risk and Metabolic Biomarkers in a Rate Model of Obesity, Menopause, and Breast Cancer  
**Erin Giles**, University of Michigan

### Advocate Perspective

**Valerie Fraser**

### Q&A

### Invited Speaker

- Breaking the Obesity-Breast Cancer Link: Diet, Drug and Surgical Strategies  
**Stephen Hursting**, University of North Carolina

### Selected Abstract Presentations

- Resistance and Aerobic Exercise for Prevention in Women with Dense Breasts (REPD): A Trial in Progress  
**Jennifer Ligibel**, Dana Farber Cancer Institute
- Time Restricted Eating and Metformin (TEAM) in Invasive Breast Cancer or DCIS: A Randomized Window of Opportunity Trial. Preliminary Safety Analysis  
**Irene Maria Briata**, E.O. Ospedali Galliera



## RISE UP for Breast Cancer

- Low dose Tamoxifen and Lifestyle changes for breast cancer prevention (TOLERANT Study): Study Protocol of a Randomized Phase II Biomarker Trial in Women at Increased Risk for Breast Cancer

**Matteo Lazzeroni**, European Institute of Oncology IRCCS

### Advocate Perspective

**Valerie Fraser**

### Q&A

#### Summary

**Andrea De Censi**, Co-Chair

#### Persistence in Prevention Award

Presented by Laura Esserman and Judy Garber

11:30-1:15pm

### Poster Session 2: Prevention Studies in Progress Lunch

12:30-2:00pm

### Optional Event: Luncheon (Tickets Required)

2:15-3:45pm

### Session 6: The Consequences of the Dobbs Decision: A Look at the Impact in Women's Health Chair:

**Daniel Grossman**, University of California, San Francisco

- The Effect of the *Dobbs* Decision on Patients and Providers Nationally and in the Southeast  
**Jamila Perritt**, Physicians for Reproductive Health
- Care Post-Roe Study: Documenting Poor Quality Care Since *Dobbs*  
**Daniel Grossman**, University of California, San Francisco
- The Turnaway Study and End of Roe Study  
**Diana Greene Foster**, University of California, San Francisco
- Effects of *Dobbs* on Medical Education  
**Josie Urbina**, University of California, San Francisco
- Q&A and Discussion

4:00-5:00pm

### Session 7: Panel: Breast Cancer and Maternal Mortality Disparities in African American Women: Connection or Coincidence?

**Co-Chairs:** **Olufunmilayo (Funmi) Olopade**, University of Chicago  
**Andrea Jackson**, University of California, San Francisco

**Advocate:** **Ricki Fairley**, Touch, The Black Breast Cancer Alliance

#### Introduction

**Andrea Jackson**, Co-Chair

#### Invited Speakers

- Infertility and Pelvic Floor Disorders in Black Women  
**Oluwateniola (Teni) Brown**, Northwestern University
- Obesity, Inflammation and Uterine Fibroids



## RISE UP for Breast Cancer

**Obianuju Sandra Madueke-Laveuax**, University of Chicago

- Evolutionary trajectory of breast cancer in diverse populations  
**Funmi Olopade**, University of Chicago
- Targeting inflammatory pathways in breast cancer (examples from I-SPY)  
**Frederick Howard**, University of Chicago

### Advocate Perspective

**Ricki Fairley**, TOUCH, The Black Breast Cancer Alliance

### Panel Discussion and Q&A

5:00-5:45pm

### Session 8: Equitable Access: Tackling Barriers in Clinical Trial Diversity

**Co-Chairs:** **Sara Horton**, Quantum Leap Healthcare Collaborative and Howard University  
**Kim Rhoads**, University of California, San Francisco

**Advocates:** **Maimah Karmo**, Tigerlily Foundation  
**Jan Tomlinson**, UCSF Breast Science Advocacy Core

#### Introduction and Welcome

- Co-chairs **Sara Horton** and **Kim Rhoads**

#### Panel 1: Case Study - ISPY 2 Trial and ACCESS Initiative

- USC/LA County PI  
**Priya Jayachandran**
- USC Research Coordinator  
**Dominic Zavala**
- Advocate  
**Jan Tomlinson**

#### Panel 2: Financial Barriers and Insurance Coverage in Clinical Trials

- SB 37 (California) and proposed National Clinical Trials Coverage Act  
**Laura Esserman**
- Patient Support and Resources  
**Dana Dornsife**, Founder, Lazarex Cancer Foundation  
**Maimah Karmo**, President and Founder, TigerLily Foundation

#### Interactive Q&A Session

#### Closing Remarks

- Co-chairs **Sara Horton** and **Kim Rhoads**

5:45-7:00pm

**Poster Session 3: Environmental Exposures, Novel Prevention Strategies, Risk Prediction, Risk Factors**  
**Appetizers**

## Sunday, November 3

7:00-8:00am

**Poster Session 4: Cycle Control, Post-partum Weaning, Menopause Control, Modifiable Risk Factors, I2I Entries**  
**Breakfast**



## RISE UP for Breast Cancer

8:00-8:30am

### Session 9: Lecture: The Science of the Sex Hormone Ecosystem Across a Women's Lifetime

**Introduction:** Doug Yee, University of Minnesota  
**Invited Speaker:** Carol Lange, University of Minnesota

8:30-9:45am

### Session 10: Postpartum Breast Cancer: Opportunities for Improving Treatment and Prevention

**Chair:** Virginia Borges, University of Colorado, Anschutz  
**Advocate:** Lynda Weatherby, Our MBC Life Podcast

#### Introduction

*Virginia Borges*, Chair

#### Advocate Perspective

*Lynda Weatherby*

#### Invited Speaker

- Studies of postpartum breast cancer inform novel treatment options  
*Traci Lyons*, University of Colorado, Anschutz

#### Selected Abstract Presentations

- Breastfeeding Attributable Risk of Triple Negative Breast Cancer in the US  
*Lajos Pusztai* (on behalf of *Rachel Jaber Chehayeb*, University of Pennsylvania)
- PPBC Vit D Liver Metabolism  
*Pepper Schedin*, Oregon Health Sciences University (OHSU)
- Identifying Gaps in Care Among Patients with Pregnancy and Post-Partum Associated Breast Cancer  
*Malcom Su*, University of Texas Southwestern

#### Panel Discussion and Q&A

10:15-11:15am

### Session 11: Making Prevention and Holistic Care a Priority in Women's Health

**Chair:** Elizabeth (Beth) Garner  
**Advocate:** Vivian Lee, UCSF Breast Science Advocacy Core

#### Introduction

*Beth Garner*

#### Invited Speakers

- Regulatory Considerations in Women's Health Prevention  
*Janet Woodcock*
- Challenges and Barriers to Innovation and Contraception Research  
*Diana Blithe*
- All Progestins Are Not the Same  
*Donita Africander*

**Interdisciplinary Panel:** The underinvestment and health economics in women's health and prevention broadly, setting the impetus for investment in these types of products

- *Andrea Olariu*, Medicines360
- *Julia Kepniss*, Brem Foundation to Defeat Breast Cancer
- *Liz Powell*, G2G Consulting and Former Legislative Director in Congress
- *Vivian Lee*, Advocate



## RISE UP for Breast Cancer

11:15-12:45pm

### Session 12: Ideas to Implementation: Incorporating Breast Cancer Prevention into a Holistic Approach to Women's Health

#### Judges Panel

**Advocate:** *Susie Brain*, UCSF Breast Science Advocacy Core

- Introduction & Introduction to Judges (Laura Esserman)
- Pitch 1
  - Pitch 1 Feedback
- Pitch 2
  - Pitch 2 Feedback
- Pitch 3
  - Pitch 3 Feedback
- Pitch 4
  - Pitch 4 Feedback
- Conclusion (Doug Yee and Laura Esserman)
- Winner Announcement





RISE UP for Breast Cancer



# RISE UP for Breast Cancer

Revolutionizing Investigations to  
**StEp Up Prevention**

Platinum

**AstraZeneca**

**Silver**

Atossa Therapeutics

Breast Cancer Research Foundation

California Breast Cancer Research

Program Novartis

Quantum Leap Healthcare Collaborative

**Bronze**

Agendia

Daiichi-Sankyo

Dana-Farber Cancer

Hotel Nikko

Institute Exai Bio Inc.

Gilead Sciences, Inc.

Masonic Cancer Center,

University of Minnesota

Medicines360

National Cancer Institute

Stemline Therapeutics, A Menarini  
Group Company

UCSF Helen Diller Family

Comprehensive Cancer Center

UCSF School of Medicine